Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: ACAN who wrote (61867)	2/26/2007 3:26:41 PM
From: Stuki	Read Replies (1) \| Respond to of 120409

RPBIF doing nicely the last few days. They seem to be moving in the direction and on target that Rob Pilz, their CFO mentioned to me on 10/30/06. Following is my report of that phone call. RPBIF Rob Pilz the CFO returned my phone call. He said the test, a diagnostic for congestive heart failure has also been established as a marker for prognosis in ACS (Acute Coronary Syndrome) entails 600 people of which it is 80% completed. They are crunching the data as they go. At this point he said, "the data looked terrific." He said they were getting the kind of results to match their earlier data that prompted them to go ahead with the test. They must show "substantial equivalence" to the predicate test. He was very optimistic. He said the FDA usually decides within 90-120 days from the time the completed data is submitted. He expects the test to be marketed in the USA by Q2, 2007 and earlier in the EU and perhaps China. They do their own manufacturing but will do strategic partnerships for sales and distribution. They plan to keep control of the manufacturing for next many years. They plan to market the test around the world aside from Japan, where they have a strategic partnership with Shinogi already. Part of the advantage of their test is the quick turn around time and the possibility of evaluating the test at "point of care." That is not always necessary once a diagnosis is done, but can be very important in an emergency room setting or a doctors office. He said for instance, it can be difficult in an emergency room to tell the difference between CHF and pneumonia. He said the company will be working on a flu test this coming flu season and perhaps a bird flu test. Their second area of concern after heart problems is infectious disease. He said their "ramp" platform is a terrific platform for developing tests. He said they have not failed outperforming any predicate test in any area they have developed a test. The company fully diluted is roughly 120 M shares, O/S about 98 M and float of about 48 M. That is what I remember of our conversation. I hope it is of some help. Mr Pilz never rushed the conversation and answered straightforwardly. If he did not know some thing, he said so.